Innovent Biologics, Inc. (OTCMKTS:IVBXF – Get Free Report) traded down 3.7% during mid-day trading on Tuesday . The stock traded as low as $4.43 and last traded at $4.43. 800 shares were traded during mid-day trading, a decline of 100% from the average session volume of 237,210 shares. The stock had previously closed at $4.60.
Innovent Biologics Price Performance
The company’s 50 day simple moving average is $4.94 and its 200-day simple moving average is $5.15.
Innovent Biologics Company Profile
Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.
Featured Articles
- Five stocks we like better than Innovent Biologics
- Canadian Penny Stocks: Can They Make You Rich?
- Comprehensive PepsiCo Stock Analysis
- What is the FTSE 100 index?
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Using the MarketBeat Dividend Yield Calculator
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Innovent Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovent Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
